Decheng Capital LLC 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Decheng Capital LLC disclosed 14 US equity positions worth $731.7m in its Q2 2026 13F filing. The largest position was CGON at 61.9% of the reported book, followed by NUVB and AARD. Against the Q1 2026 filing, it opened 1 new position, added to 0 and reduced 3 among the top 14 holdings.
What did Decheng Capital LLC own in Q2 2026? Top 14 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | CGON CG ONCOLOGY INC | Healthcare | 61.9% | $452.7m | 6,371,669 | 0% | held |
| 2 | NUVB Nuvation Bio Inc. | Healthcare | 20.1% | $147.4m | 25,954,439 | 0% | held |
| 3 | AARD AARDVARK THERAPEUTICS INC | 3.1% | $22.6m | 3,917,299 | 0% | held | |
| 4 | ACRS Aclaris Therapeutics, Inc. | Healthcare | 2.9% | $21.4m | 4,041,736 | 0% | held |
| 5 | UPB Upstream Bio Inc. | 2.6% | $18.9m | 2,724,868 | 0% | held | |
| 6 | RCUS Arcus Biosciences, Inc | Healthcare | 2.0% | $14.3m | 464,779 | -3% | reduced |
| 7 | EQ Equillium Inc. | 1.9% | $14.2m | 4,447,308 | 0% | held | |
| 8 | RVMD REVOLUTION MEDICINES INC(NSM) | Healthcare | 1.3% | $9.9m | 52,667 | -44% | reduced |
| 9 | LYEL Lyell Immunopharma, Inc. | 1.3% | $9.7m | 692,050 | 0% | held | |
| 10 | BYSI BeyondSpring Inc. | 0.9% | $6.7m | 3,800,702 | 0% | held | |
| 11 | ZNTL Zentalis Pharmaceuticals Inc. | Healthcare | 0.9% | $6.4m | 1,323,327 | 0% | held |
| 12 | NEWAMSTERDAM PHARMA CO NV | 0.8% | $6.0m | 176,887 | -46% | reduced | |
| 13 | PYXS Pyxis Oncology, Inc (formerly Apexigen) | 0.1% | $983.7k | 326,810 | 0% | held | |
| 14 | TNGX TANGO THERAPEUTICS INC | Healthcare | 0.1% | $625.2k | 20,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.